- 1. C pylori
- [ ] (UMLS (CSP) C0599792) =Bacterium ;
| - 18. CpG ODN
- [A synthetic oligodeoxynucleotide containing multiple repeats of unmethylated CpG motifs (CpG ODN) with immunostimulatory activity. Upon entering the cell via endocytosis, CpG-28 activates numerous signaling transduction pathways resulting in the release of multiple cytokines. CpG-28 has immunomodulatory properties with direct activation of B-lymphocytes, dendritic and NK cells resulting in the stimulation of innate immunity and antibody-dependant cell cytotoxicity (ADCC). Additionally, this agent indirectly modulates T-cell responses though the release of cytokines (IL-12 and IFN gamma) to induce a preferential shift to the Th1 (helper) phenotype resulting in enhanced CD8+ cellular cytotoxicity. ( NCI )] (UMLS (NCI) C0914671) CpG oligodeoxynucleotide;
CpG-28;
CpG-28 Oligodeoxynucleotide;
=Nucleic Acid, Nucleoside, or Nucleotide; Pharmacologic Substance ;
|
- 2. CP
- (UMLS (NCI) C0280003) =Therapeutic or Preventive Procedure
| - 19. CPI-B
- [Encoded by human CST6 Gene, 149-amino acid 16.5 kD (precursor) Cystatin 6 is a type 2 cystatin. Cystatin superfamily proteins contain multiple cystatin-like sequences. Three inhibitory subfamilies display structural and functional similarities: type 1 stefins, type 2 cystatins, and kininogens. Some members are cysteine protease inhibitors, while others have lost or never acquired inhibitory activity. Type 2 cystatins are endogenous intracellular or extracellular cysteine proteinase inhibitors that appear to provide protective functions. (from Swiss-Prot, OMIM, and NCI) ( NCI )] (UMLS (NCI) C0534343) =Amino Acid, Peptide, or Protein; Pharmacologic Substance
|
- 3. CP 62993
- (UMLS (NCI) C0729049) =Organic Chemical; Antibiotic ;
| - 20. cPLA2
- [Cytosolic phospholipase A2 is involved in cell cycle progression via regulation of arachidonic acid metabolism. (Cell Mol Life Sci 2002;59:181-8) ( NCI )] (UMLS (NCI) C1333201) Cytosolic Phospholipase A2;
Cytosolic Phospholipase A2 Group IV;
Cytosolic Phospholipase A2G4;
Cytosolic Phospholipase A2IV;
Phospholipase A2G4;
Phospholipase A2IV =Amino Acid, Peptide, or Protein; Enzyme |
- 4. CP range type
- (UMLS (HL7) C1547698) =Idea or Concept ;
=HL7 Vocabulary Version 2.5;
=Flat-rate. Apply the entire price to this interval, do not pro-rate the price if the full interval has not occurred/been consumed;
Pro-rate. Apply this price to this interval, pro-rated by whatever portion of the interval has occurred/been consumed | - 21. cPLA2 Interacting Protein
- [TIP60 interacts with the activation domain of Tat, an activator of HIV gene expression. The yeast SAS2 transcriptional silencing protein, important for exit from the cell cycle, is closely related to TIP60. The widely expressed cell surface amyloid-beta precursor protein is cleaved by gamma-secretase and its cytoplasmic tail forms a multimeric complex with the nuclear adaptor protein FE65 and the histone acetyltransferase TIP60. This complex potently stimulates transcription. (from OMIM 601409 and NCI) ( NCI )] (UMLS (NCI) C1336632) HIV-1 Tat Interactive Protein, 60kDa;
HTATIP;
TAT Interacting Protein 60;
TIP60 =Amino Acid, Peptide, or Protein; Enzyme |
- 5. CP-358,774
- (UMLS (NCI) C0910101) =Organic Chemical; Pharmacologic Substance
| - 22. CPT Modifier Code
- (UMLS (HL7) C1550193) =Intellectual Product =Code;
|
- 6. CP-609,754
- [A substance that is being studied as an anticancer drug. ( NCI )] (UMLS (NCI) C0879599) =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor
| - 23. CPT-11/dFdC
- (UMLS (NCI) C0677796) =Therapeutic or Preventive Procedure
|
- 7. CP-724,714
- [An orally bioavailable quinazoline with potential antineoplastic activity. CP-724,714 selectively binds to the intracellular domain of HER2, reversibly inhibiting its tyrosine kinase activity and resulting in suppression of tumor cell growth. HER2, a member of the epidermal growth factor receptor (EGFR) family, is overexpressed in many adenocarcinomas, particularly breast cancers. (NCI04) ( NCI )] (UMLS (NCI) C1327906) =Organic Chemical; Pharmacologic Substance
| - 24. CPT-11/DM/FUDR
- (UMLS (NCI) C0796486) Dexamethasone/Floxuridine/Irinotecan =Therapeutic or Preventive Procedure
|
- 8. CP25
- [Encoded by HOXC6 Gene (ANTP Family), 153- and 235-amino acid (27-kD) Homeobox C6 Protein isoforms are highly conserved sequence-specific DNA-binding homeobox transcription repressors that can cooperate with other HOX proteins and may contribute to the breast cell phenotype through co-operative interactions. As part of a developmental regulatory system that provides anterior-posterior positional identity to cells, HOXC6 may regulate the coordinated expression of multiple genes involved in morphogenesis and differentiation. (from LocusLink, Swiss-Prot, OMIM, and NCI) ( NCI )] (UMLS (NCI) C1334039) HHO.C8;
Homeobox Protein 3C;
Homeobox Protein C6;
Homeobox Protein C8;
Homeobox Protein HOXC6;
HOX3C;
HOXC6 =Amino Acid, Peptide, or Protein; Biologically Active Substance | - 25. CPT-11/ICI D1694
- (UMLS (NCI) C0392997) =Therapeutic or Preventive Procedure
|
- 9. CP4071
- [A substance that is being studied as a treatment for cancer. ( NCI )] (UMLS (NCI) C0935876) =Pharmacologic Substance ;
| - 26. CPT-11/L-OHP
- (UMLS (NCI) C0796324) Irinotecan/Oxaliplatin;
=Therapeutic or Preventive Procedure |
- 10. CPB6
- [Expressed in liver, lung, and heart by phenobarbital-induced human CYP2B6 Gene (Cytochrome P450 Family), 491-aa 56-kDa Cytochrome P450 2B6 is an endoplasmic reticulum membrane-bound P450 heme-thiolate monooxygenase involved in an NADPH-dependent electron transport pathway that oxidizes diverse unrelated compounds, including steroids, fatty acids, and xenobiotics such as cyclophosphamide and ifosfamide. Phosphorylation may decrease CYP2B6 activity. P450 enzymes catalyze reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. (NCI) ( NCI )] (UMLS (NCI) C0534137) =Amino Acid, Peptide, or Protein; Enzyme =CYP (cytochrome P450);
| - 27. CPT-11/LY231514
- (UMLS (NCI) C0796464) Irinotecan/LY231514;
Irinotecan/Pemetrexed Disodium =Therapeutic or Preventive Procedure |
- 11. Cpd 109514
- (UMLS (NCI) C0969772) =Organic Chemical; Pharmacologic Substance ;
| - 28. CPT-11/MITO
- (UMLS (NCI) C0796482) Irinotecan/Mitomycin =Therapeutic or Preventive Procedure
|
- 12. CpG
- [A dinucleotide consisting of cytosine followed by guanine. ( NCI )] (UMLS (NCI) C0056912) =Nucleic Acid, Nucleoside, or Nucleotide; Biologically Active Substance
| - 29. CPT-11/TAX
- (UMLS (NCI) C0393019) =Therapeutic or Preventive Procedure
|
- 13. CpG 7909
- [A synthetic 24-mer oligonucleotide containing 3 CpG motifs with potential antineoplastic and immunostimulatory activity. CpG 7909 selectively targets Toll-like receptor 9 (TLR9), thereby activating dendritic and B cells and stimulating cytotoxic T cell and antibody responses against tumor cells bearing tumor antigens. (NCI05) ( NCI )] (UMLS (NCI) C1134664) =Nucleic Acid, Nucleoside, or Nucleotide; Pharmacologic Substance ;
| - 30. CPT-4
- [American Medical Association, P.O. Box 10946, Chicago IL 60610. ( HL7V3.0 )] (UMLS (HL7) C1140095) =Intellectual Product =Code;
CodeSystem |
- 14. CpG 7909/Dacarbazine
- (UMLS (NCI) C1328141) =Therapeutic or Preventive Procedure ;
| - 31. CPT-5
- [American Medical Association, P.O. Box 10946, Chicago IL 60610. ( HL7V3.0 )] (UMLS (HL7) C1550186) =Intellectual Product =Code;
CodeSystem |
- 15. CpG 7909/Rituximab
- (UMLS (NCI) C1134705) =Therapeutic or Preventive Procedure ;
| - 32. CPTR/LHRH
- (UMLS (NCI) C0678022) =Therapeutic or Preventive Procedure
|
- 16. CpG 7909/Trastuzumab
- (UMLS (NCI) C1134665) =Therapeutic or Preventive Procedure
| - 33. CPTR/ZDX
- (UMLS (NCI) C0278821) =Therapeutic or Preventive Procedure
|
- 17. CpG island
- [Short region of DNA in which the frequency of the CG sequence is higher than in other regions. ( NCI )] (UMLS (CSP) C0282523) =Nucleic Acid, Nucleoside, or Nucleotide; Biologically Active Substance =nucleic acid sequence;
| - 34. CPV (cytoplasmic polyhedrosis virus)
- [ ] (UMLS (CSP) C0205934) =Virus ;
|
home
